Yıl: 2023 Cilt: 12 Sayı: 1 Sayfa Aralığı: 8 - 19 Metin Dili: Türkçe DOI: 10.5336/pharmsci.2022-90431 İndeks Tarihi: 24-05-2023

Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme

Öz:
Nörodejeneratif hastalıklardan biri olan Alzheimer hastal ığı (AH), günümüzde yayg ın olarak görülen ve haf ıza kaybı, bilişsel iş- levlerde bozulma ve ilerleyen zamanlarda günlük aktiviteleri yerine ge- tirememeyle kendini gösteren bir demans türüdür. Sadece palyatif tedavisi olan bu hastal ıkta, beyinde kademeli olarak artan ve geri dö- nüşümü olmayan bir hasar meydana gelmektedir. Bu hastal ığın etiyo- lojini araştırmak için son yıllarda çok sayıda in vitro ve in vivo model geliştirilmektedir. Araştırmacılar, hayvan modelleri ile AH’nin lez- yonlarını, semptomlarını veya nedenlerini taklit etmeye çalışmaktadır. AH üzerine yap ılan araştırmalarda, hayvan kullanman ın çeşitli avan- tajları bulunmaktadır. AH hayvan modelleri geli ştirilirken, hastalıkta “amiloid plak” ve “nörofibriler yumaklar ın” birikimi oldu ğu için “ β- amiloid” ve “Tau proteini” modelleri üzerine odaklanılmıştır. Bu farklı modeller, araştırıcıların manipülasyon yeteneklerini artırabilmektedir. Ayrıca deney hayvanlarının yaşam süresi kısa olduğu için modeli oluş- turmak ve sonuçlarını görmek hızlı bir şekilde gerçekleşebilmektedir ve kararlı laboratuvar koşulları, çevresel ve fizyolojik etmenlerin etkisini azaltmaktadır. Hayvanlardaki fizyolojik değişiklikler de daha yakından izlenebilmektedir. Ancak bu modeller, AH’nin temel özelliklerini or- taya çıkarsa da hiçbiri insan beyninde gözlenen patolojik özellikleri tam olarak taklit etmemektedir. Geli ştirilen AH modelleri, genel olarak “transgenik” ve “transgenik olmayan” hayvanlar üzerinde yapılmakta- dır. Transgenik hayvan modeli olarak, çalışmaların büyük bir kısmında fareler kullanılmaktadır. Bu geleneksel derlemede, AH araştırmalarında kullanılan in vivo modelleri olan Tg2576, APP23, PDAPP, PSEN1, JNPL3 ve TAPP fare modelleri hakkında güncel bilgiler özetlenmiş ve bu modellerin üstünlükleri ve dezavantajları tartışılmıştır.
Anahtar Kelime:

Alzheimer’s Disease In Vivo Models: A Traditional Review

Öz:
Alzheimer’s disease (AD), a neurodegenerative disease, is a common dementia that presents itself with memory loss, deterio- ration in cognitive functions and inability to perform daily activities in the future. In this disease, which has only palliative treatment, grad- ual increase and irreversible damage in the brain occurs. Numerous in vitro and in vivo models have been developed in recent years to in- vestigate the etiology of the disease. Researchers are trying to mimic the lesions, symptoms or causes of AD with animal models. There are several advantages of using animals in research on AD. Animal models of AD have focused on “β-amyloid” and “Tau protein” mod- els because of the accumulation of “amyloid plaque” and “neurofib- rillary tangles” in the disease. These different models can increase manipulation abilities of researchers. In addition, since life span of experimental animals is short, creating the model and seeing the re- sults can be faster and under stable laboratory conditions, effects of environmental and physiological factors can be reduced. Physiologi- cal changes in animals can also be monitored more closely. However, although these models reveal basic features of AD, none of them fully mimic the pathological features observed in the human brain. Devel- oped AD models are generally performed on “transgenic” and “non- transgenic” animals. Mice are used in the majority of transgenic animal models. In this traditional review, up-to-date information about Tg2576, APP23, PDAPP, PSEN1, JNPL3 and TAPP mouse models, which are in vivo models used in AD research, are compiled and advantages and disadvantages of these models are discussed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Alzheimer's Association Report. Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2017;13(4):325-73. [Crossref]
  • 2. World Health Organization. Global action plan on the public health response to dementia 2017-2025. Cited: April 06, 2022. Available from: [Link]
  • 3. Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A. Sex and gender differ- ences in Alzheimer's disease: recommendations for future research. J Wom- ens Health (Larchmt). 2012;21(10):1018-23. [Crossref] [PubMed]
  • 4. Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer's disease. Mol Neurodegener. 2017;12(1):89. [Crossref] [PubMed] [PMC]
  • 5. Puzzo D, Gulisano W, Palmeri A, Arancio O. Rodent models for Alzheimer's disease drug discovery. Expert Opin Drug Discov. 2015;10(7):703-11. [Cross- ref] [PubMed] [PMC]
  • 6. Faber-Langendoen K, Morris JC, Knesevich JW, LaBarge E, Miller JP, Berg L. Aphasia in senile dementia of the Alzheimer type. Ann Neurol. 1988;23(4):365-70. [Crossref] [PubMed]
  • 7. Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer TA. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol. 2006;111(4):312-9. [Crossref] [PubMed]
  • 8. Chabrier MA, Neely KM, Castello NA, Frank M. The Contribution of Trans- genic Models to the understanding of Alzheimer's Disease Progression and Therapeutic Development. Avila J, Lucas JJ, Hernández F, eds. Animal Mod- els for Neurodegenerative Disease. 1st ed. Cambridge, uK: Royal Society Chemistry; 2011. p.1-14. [Crossref]
  • 9. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512):797-811. [Crossref] [PubMed]
  • 10. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in differ- ent age categories. Neurobiol Aging. 1997;18(4):351-7. [Crossref] [PubMed]
  • 11. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Ihara Y. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol. 1988;76(6):541-9. [Cross- ref] [PubMed]
  • 12. Bird TD. Genetic factors in Alzheimer disease and dementia. In: Speicher MR, Motulsky AG, Antonarakis SE, eds. Vogel and Motulsky's Human Ge- netics. 4th ed. Berlin, Heidelberg: Springer; 2010. p.681-97.
  • 13. Götz J, Götz NN. Animal models for Alzheimer's disease and frontotemporal dementia: a perspective. ASN Neuro. 2009;1(4):e00019. [Crossref] [PubMed] [PMC]
  • 14. Dorszewska J, Prendecki M, Oczkowska A, Dezor M, Kozubski W. Molecu- lar basis of familial and sporadic Alzheimer's disease. Curr Alzheimer Res. 2016;13(9):952-63. [Crossref] [PubMed]
  • 15. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383(6602):710-3. [Crossref] [PubMed]
  • 16. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reap- praisal. J Neurochem. 2009;110(4):1129-34. [Crossref] [PubMed]
  • 17. LaFerla FM, Green KN. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(11):a006320. [Crossref] [PubMed] [PMC]
  • 18. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002;9(2):88-102. [Crossref] [PubMed]
  • 19. Burbach GJ, Hellweg R, Haas CA, Del Turco D, Deicke u, Abramowski D, et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci. 2004;24(10):2421-30. [Crossref] [PubMed] [PMC]
  • 20. Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer's dis- ease. Pharmacol Ther. 2014;142(2):244-57. [Crossref] [PubMed]
  • 21. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque- independent disruption of neural circuits in Alzheimer's disease mouse mod- els. Proc Natl Acad Sci u S A. 1999;96(6):3228-33. [Crossref] [PubMed] [PMC]
  • 22. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid pro- tein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20(11):4050-8. [Crossref] [PubMed] [PMC]
  • 23. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hy- pothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci. 2000;924:17-25. [Crossref] [PubMed]
  • 24. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, et al. Reversal of Alzheimer's-like pathology and behavior in human APP trans- genic mice by mutation of Asp664. Proc Natl Acad Sci u S A. 2006;103(18):7130-5. Erratum in: Proc Natl Acad Sci u S A. 2007;104(16):6876. [Crossref] [PubMed] [PMC]
  • 25. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hip- pocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55(5):697-711. [Crossref] [PubMed] [PMC]
  • 26. Beauquis J, Pavía P, Pomilio C, Vinuesa A, Podlutskaya N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. Exp Neurol. 2013;239:28-37. [Crossref] [PubMed]
  • 27. Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disrup- tion of neurogenesis by amyloid beta-peptide, and perturbed neural progen- itor cell homeostasis, in models of Alzheimer's disease. J Neurochem. 2002;83(6):1509-24. [Crossref] [PubMed]
  • 28. Sarasa M, Pesini P. Natural non-trasgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res. 2009;6(2):171-8. [Crossref] [PubMed] [PMC]
  • 29. Axelman K, Basun H, Winblad B, Lannfelt L. A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein muta- tion. A clinical and genealogical investigation. Arch Neurol. 1994;51(12):1193- 7. [Crossref] [PubMed]
  • 30. Esquerda-Canals G, Montoliu-Gaya L, Güell-Bosch J, Villegas S. Mouse models of Alzheimer's disease. J Alzheimers Dis. 2017;57(4):1171-83. [Cross- ref] [PubMed]
  • 31. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Cor- relative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99-102. [Crossref] [PubMed]
  • 32. George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G, et al. APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis. 2004;16(1):124-32. [Crossref] [PubMed]
  • 33. Barrett JE, McGonigle P. Rodent Models for Alzheimer's Disease in Drug Dis- covery. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders. 2017;235-47. [Crossref] [PubMed] [PMC]
  • 34. Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice over- expressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22(17):7380-8. [Crossref] [PubMed] [PMC]
  • 35. AbdAlla S, Langer A, Fu X, Quitterer u. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease. Int J Mol Sci. 2013;14(8):16917-42.[Crossref] [PubMed] [PMC]
  • 36. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci u S A. 1997;94(24):13287-92. [Crossref] [PubMed] [PMC]
  • 37. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr Alzheimer Res. 2009;6(2):137-43. [Crossref] [PubMed]
  • 38. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, et al. Locus ceruleus degeneration promotes Alzheimer patho- genesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006;26(5):1343-54. [Crossref] [PubMed] [PMC]
  • 39. Beckmann N, Schuler A, Mueggler T, Meyer EP, Wiederhold KH, Staufenbiel M, et al. Age-dependent cerebrovascular abnormalities and blood flow dis- turbances in APP23 mice modeling Alzheimer's disease. J Neurosci. 2003;23(24):8453-9. [Crossref] [PubMed] [PMC]
  • 40. Choi JH, Kaur G, Mazzella MJ, Morales-Corraliza J, Levy E, Mathews PM. Early endosomal abnormalities and cholinergic neuron degeneration in amy- loid-β protein precursor transgenic mice. J Alzheimers Dis. 2013;34(3):691- 700. [Crossref] [PubMed] [PMC]
  • 41. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373(6514):523-7. [Crossref] [PubMed]
  • 42. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw trans- genic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56(9):965-73. [Crossref] [PubMed]
  • 43. Su Y, Ni B. Selective deposition of amyloid-beta protein in the entorhinal-den- tate projection of a transgenic mouse model of Alzheimer's disease. J Neu- rosci Res. 1998;53(2):177-86. [Crossref] [PubMed]
  • 44. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM,ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid pre- cursor protein. Behav Neurosci. 1999;113(5):982-90. [Crossref] [PubMed]
  • 45. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immu- nization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-7. [Crossref] [PubMed]
  • 46. German DC, Yazdani u, Speciale SG, Pasbakhsh P, Games D, Liang CL. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J Comp Neurol. 2003;462(4):371-81. [Crossref] [PubMed]
  • 47. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid bur- den in a mouse model of Alzheimer's disease. Ann Neurol. 2000;48(4):567- 79. [Crossref] [PubMed]
  • 48. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci u S A. 2001;98(15):8850-5. [Crossref] [PubMed] [PMC]
  • 49. Donovan MH, Yazdani u, Norris RD, Games D, German DC, Eisch AJ. De- creased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol. 2006;495(1):70-83. [Crossref] [PubMed]
  • 50. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17(3):263-4. [Crossref] [PubMed]
  • 51. Selwood SP, Parvathy S, Cordell B, Ryan HS, Oshidari F, Vincent V, et al. Gene expression profile of the PDAPP mouse model for Alzheimer's disease with and without Apolipoprotein E. Neurobiol Aging. 2009;30(4):574-90. [Crossref] [PubMed]
  • 52. Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen Š, Gubert Olivé M, et al. PSEN1 Mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer's disease. Stem Cell Reports. 2017;9(6):1885-97. [Crossref] [PubMed] [PMC]
  • 53. Liao MC, Muratore CR, Gierahn TM, Sullivan SE, Srikanth P, De Jager PL, et al. Single-cell detection of secreted Aβ and sAPPα from human IPSC-de- rived neurons and astrocytes. J Neurosci. 2016;36(5):1730-46. [Crossref] [PubMed] [PMC]
  • 54. Hoffman JL, Faccidomo S, Kim M, Taylor SM, Agoglia AE, May AM, et al. Al- cohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease. Int Rev Neurobiol. 2019;148:169-230. [Crossref] [PubMed] [PMC]
  • 55. Kim HJ, Kim DJ, Shin EJ, Lee BH, Choi SH, Hwang SH, et al. Effects of gin- tonin-enriched fraction on hippocampal cell proliferation in wild-type mice and an APPswe/PSEN-1 double Tg mouse model of Alzheimer's disease. Neu- rochem Int. 2016;101:56-65. [Crossref] [PubMed]
  • 56. Elçioğlu HK, Yılmaz G, İlhan B, Karan MA. Alzheimer hastalığında deneysel hayvan modelleri [Experimental animal models for Alzheimer disease]. Nobel Med. 2018;14(1):5-13. [Link]
  • 57. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, et al. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology dis- plays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis. 2010;20(1):113-26. [Crossref] [PubMed]
  • 58. Nilsen LH, Melø TM, Saether O, Witter MP, Sonnewald u. Altered neuro- chemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study. J Neurochem. 2012;123(4):532-41. [Crossref] [PubMed]
  • 59. Wilson EN, Do Carmo S, Welikovitch LA, Hall H, Aguilar LF, Foret MK, et al. NP03, a microdose lithium formulation, blunts early amyloid post-plaque neu- ropathology in McGill-R-Thy1-APP Alzheimer-like transgenic rats. J Alzheimers Dis. 2020;73(2):723-39. [Crossref] [PubMed]
  • 60. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegten- horst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor dis- turbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402-5. [Crossref] [PubMed]
  • 61. Vega IE, umstead A, Wygant CM, Beck JS, Counts SE. Ezrin expression is increased during disease progression in a tauopathy mouse model and Alzheimer's disease. Curr Alzheimer Res. 2018;15(12):1086-95. [Crossref] [PubMed] [PMC]
  • 62. Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic studies of antibody- mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry. 2011;2:59. [Crossref] [PubMed] [PMC]
  • 63. Fukuhara K, Ohno A, Ota Y, Senoo Y, Maekawa K, Okuda H, et al. NMR- based metabolomics of urine in a mouse model of Alzheimer's disease: iden- tification of oxidative stress biomarkers. J Clin Biochem Nutr. 2013;52(2):133-8. [Crossref] [PubMed] [PMC]
  • 64. Marquez A, Guernsey LS, Frizzi KE, Cundiff M, Constantino I, Muttalib N, et al. Tau associated peripheral and central neurodegeneration: identification of an early imaging marker for tauopathy. Neurobiol Dis. 2021;151:105273. [Crossref] [PubMed] [PMC]
  • 65. Schaeffer EL, Figueiro M, Gattaz WF. Insights into Alzheimer disease patho- genesis from studies in transgenic animal models. Clinics (Sao Paulo). 2011;66 Suppl 1(Suppl 1):45-54. [Crossref] [PubMed] [PMC]
  • 66. Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, et al. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathol- ogy in forebrain. Brain Res. 2004;1012(1-2):29-41. [Crossref] [PubMed]
  • 67. Saydoff JA, Olariu A, Sheng J, Hu Z, Li Q, Garcia R, et al.uridine prodrug im- proves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models. J Alzheimers Dis. 2013;36(4):637-57. [Crossref] [PubMed]
  • 68. Heuer E, Rosen RF, Cintron A, Walker LC. Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr Pharm Des. 2012;18(8):1159-69. [Crossref] [PubMed] [PMC]
  • 69. Toledano A, Alvarez MI, López-Rodríguez AB, Toledano-Díaz A, Fernández- Verdecia CI. [Does Alzheimer's disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (I)]. Neurologia. 2012;27(6):354-69. [Crossref] [PubMed]
  • 70. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115(1):5- 38. [Crossref] [PubMed] [PMC]
  • 71. Cavanaugh SE, Pippin JJ, Barnard ND. Animal models of Alzheimer disease: historical pitfalls and a path forward. ALTEX. 2014;31(3):279-302. [Crossref] [PubMed]
  • 72. Ashe KH. Mechanisms of memory loss in Abeta and tau mouse models. Biochem Soc Trans. 2005;33(Pt 4):591-4. [Crossref] [PubMed]
  • 73. Dodart JC, Mathis C, ungerer A. The beta-amyloid precursor protein and its derivatives: from biology to learning and memory processes. Rev Neurosci. 2000;11(2-3):75-93. [Crossref] [PubMed]
  • 74. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Compar- ative analysis of amyloid-beta chemical structure and amyloid plaque mor- phology of transgenic mouse and Alzheimer's disease brains. J Biol Chem. 2001;276(16):12991-8. [Crossref] [PubMed]
  • 75. Schwab C, Hosokawa M, McGeer PL. Transgenic mice overexpressing amy- loid beta protein are an incomplete model of Alzheimer disease. Exp Neurol. 2004;188(1):52-64. [Crossref] [PubMed]
APA TÜTÜNCÜ S, Tezel H, Balcı Ozyurt A, Yirün A, Baydar T, ERKEKOGLU P (2023). Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. , 8 - 19. 10.5336/pharmsci.2022-90431
Chicago TÜTÜNCÜ Sena,Tezel Hulya,Balcı Ozyurt Aylin,Yirün Anıl,Baydar Terken,ERKEKOGLU PİNAR Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. (2023): 8 - 19. 10.5336/pharmsci.2022-90431
MLA TÜTÜNCÜ Sena,Tezel Hulya,Balcı Ozyurt Aylin,Yirün Anıl,Baydar Terken,ERKEKOGLU PİNAR Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. , 2023, ss.8 - 19. 10.5336/pharmsci.2022-90431
AMA TÜTÜNCÜ S,Tezel H,Balcı Ozyurt A,Yirün A,Baydar T,ERKEKOGLU P Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. . 2023; 8 - 19. 10.5336/pharmsci.2022-90431
Vancouver TÜTÜNCÜ S,Tezel H,Balcı Ozyurt A,Yirün A,Baydar T,ERKEKOGLU P Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. . 2023; 8 - 19. 10.5336/pharmsci.2022-90431
IEEE TÜTÜNCÜ S,Tezel H,Balcı Ozyurt A,Yirün A,Baydar T,ERKEKOGLU P "Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme." , ss.8 - 19, 2023. 10.5336/pharmsci.2022-90431
ISNAD TÜTÜNCÜ, Sena vd. "Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme". (2023), 8-19. https://doi.org/10.5336/pharmsci.2022-90431
APA TÜTÜNCÜ S, Tezel H, Balcı Ozyurt A, Yirün A, Baydar T, ERKEKOGLU P (2023). Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi, 12(1), 8 - 19. 10.5336/pharmsci.2022-90431
Chicago TÜTÜNCÜ Sena,Tezel Hulya,Balcı Ozyurt Aylin,Yirün Anıl,Baydar Terken,ERKEKOGLU PİNAR Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi 12, no.1 (2023): 8 - 19. 10.5336/pharmsci.2022-90431
MLA TÜTÜNCÜ Sena,Tezel Hulya,Balcı Ozyurt Aylin,Yirün Anıl,Baydar Terken,ERKEKOGLU PİNAR Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi, vol.12, no.1, 2023, ss.8 - 19. 10.5336/pharmsci.2022-90431
AMA TÜTÜNCÜ S,Tezel H,Balcı Ozyurt A,Yirün A,Baydar T,ERKEKOGLU P Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi. 2023; 12(1): 8 - 19. 10.5336/pharmsci.2022-90431
Vancouver TÜTÜNCÜ S,Tezel H,Balcı Ozyurt A,Yirün A,Baydar T,ERKEKOGLU P Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi. 2023; 12(1): 8 - 19. 10.5336/pharmsci.2022-90431
IEEE TÜTÜNCÜ S,Tezel H,Balcı Ozyurt A,Yirün A,Baydar T,ERKEKOGLU P "Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme." Literatür Eczacılık Bilimleri Dergisi, 12, ss.8 - 19, 2023. 10.5336/pharmsci.2022-90431
ISNAD TÜTÜNCÜ, Sena vd. "Alzheimer Hastalığı İn Vivo Modelleri: Geleneksel Derleme". Literatür Eczacılık Bilimleri Dergisi 12/1 (2023), 8-19. https://doi.org/10.5336/pharmsci.2022-90431